Search Results
54 protocol(s) meet the specified criteria
100703Open  
Phase IA Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent to Subjects with Locally Advanced or Metastatic Solid Tumors

100704Open  
Phase I/II, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination with a PD-1 Inhibitor and Chemotherapy in Subjects with Advanced or Metastatic Solid Tumors (ECHO-207)

100890Open  
Phase IB (Open-Label) / Phase II (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine with or without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

101981Open  
Phase I/II Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma

102829Open  
Phase IB Dose-Escalation Study of Cabozantinib Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

102932Open  
Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)

103123Open  
Multicenter, Phase I, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

103706Open  
Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies

103711Open  
Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)

40005Open  
Phase I/II Dose-Escalation Safety, Pharmacokinetic, and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 in Patients with Selected CD38+ Hematological Malignancies

43948Open  
Multi-Tracer PET Assessment of Response in Various Malignancies in Investigational and Recently Approved Therapeutic Agents

44704Open  
Assessment of Primary and Metastatic Brain Tumor Hypoxia with 18F-Fluoromisonidazole, [18F]fluoro-2-deoxy-D-glucose (FDG) and [15O]water (H215O)

55264Open  
Phase IB/II Study of Repeat Radiation, Minocycline, and Bevacizumab in Patients with Recurrent Glioma (RAMBO)

66550Open  
Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors

71940Open  
Stereotactic Radiosurgery Dose Escalation for Brain Metastases

76066Open  
Phase IB/II, Multicenter, Trial of Talimogene Laherparepvec in Combination with Pembrolizumab (MK-3475) for Treatment of Unresectable, Stage IIIB to IVM1c Melanoma (MASTERKEY-265)

76853Open  
Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

79885Open  
Open-Label, Dose-Escalation and Multicenter Study to Evaluate the Safety and Pharmacokinetics of SAR650984 in Patients with Relapsed/Refractory Multiple Myeloma

80314Open  
Development of Quantitative Imaging Biomarkers for Evaluating Sarcoma Patients

81405Open  
Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

82223Open  
Open-Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients with Advanced Malignancies

82831Open  
Phase I/II, Open-Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies

83801Open  
Multicenter, Open-Label, Phase IB/II Study to Evaluate the Safety and Efficacy of RX-0201 in Combination with Everolimus to Treat Subjects with Advanced Renal Cell Carcinoma

83992Open  
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma

84004Open  
Molecular Analysis for Therapy Choice (MATCH)

86211Open  
Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

87144Open  
Phase IB Trial of a Combination of mFOLFIRI with MEK162 in Patients with Advanced KRAS Positive Metastatic Colorectal Cancers

87238Open  
Phase I/II Study of Intratumoral G100 Therapy in Patients with Follicular Non-Hodgkin Lymphoma

87427Open  
Phase IA/IB Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers

87559Open  
Phase I/II Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer

87799Open  
Phase I Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type

88158Open  
Open-Label, Phase IB Study of Palbociclib (Oral CDK 4/6 inhibitor) plus Abraxane (Nab-Paclitaxel) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

88893Open  
Phase IB Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients with Advanced Melanoma

88980Open  
Phase I Dose-Escalation Study Evaluating the Safety and Tolerability of PF-06671008 in Patients with Advanced Solid Tumors

89466Open  
Phase IB, Open-Label, Multicenter, Dose-Escalation Trial of Intratumoral Injections of SD-101 in Combination with Pembrolizumab in Patients with Metastatic Melanoma

89510Open  
STARTRK-2 (Studies of Tumor Alterations Responsive to Targeting Receptor Kinases-2): An Open-Label, Multicenter, Global, Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

89837Open  
Phase I, Open-Label, Dose-Escalation Study of SGN-CD19B in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

90576Open  
Phase I, Open-Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors or Lymphomas

90642Open  
Phase I, Dose-Finding, and Signal-Seeking Study of the Safety and Efficacy of Intravenous Cavataktm Alone and in Combination with Pembrolizumab in Patients with Late Stage Solid Tumours (NSCLC and Bladder Cancer)

93064Open  
Phase I/II, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Advanced Malignancies

93426Open  
Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

94141Open  
Phase I, Multicenter, Open-Label Study of Oral ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

94144Open  
Phase IB, Open-Label, Multicenter Study to Characterize the Safety, Tolerability, and Pharmacodynamics (PD) of PDR001 in Combination with LCL161, Everolimus (RAD001), or Panobinostat (LBH589)

94441Open  
Phase IB Study Evaluating the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination with Immunomodulatory Agents in Patients with Acute Myeloid Leukemia

94446Open  
Phase I/II, Single-Arm, Open-Label Study of Ribociclib in Combination with Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women with HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor

95588Open  
Open-Label, Dose-Finding, and Proof-of-Concept Study of the PD-L1 Probody Therapeutic, CX-072, as a Monotherapy and in Combination with Yervoy® (Ipilimumab) or with Zelboraf® (Vemurafenib) in Anti-PD-1/PD-L1 Inhibitor Naïve Subjects with Advanced or Recurrent Solid Tumors or Lymphomas

95981Open  
Phase IB Study of OMP-305B83 plus FOLFIRI in Subjects with 2nd-Line Metastatic Colorectal Cancer

97412Open  
Open-Label Phase I/II Study of INCB039110 in Combination with Osimertinib in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

97417Open  
Phase I/IIA First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors

97422Open  
Phase I/IB Study of Subcutaneous Recombinant Human hetIL-15 Alone and in Combination with PDR001 in Adults with Metastatic Cancers

99128Open  
Open-Label Phase I/IIA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients with Metastatic Castration-Resistant Prostate Cancer

99707Open  
Phase I, Non-Randomized, Open-Label/Phase II Randomized, Blinded Study of ProTmune versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies

99903Open  
Proof-of-Concept, Pilot Study of Pembrolizumab in Patients with Recurrent Malignant Glioma with a Hypermutator Phenotype

99906Open  
Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors